Saturday, August 23, 2025

Cresco Labs Posts 1.8% Sequential Revenue Growth In Second Quarter

Cresco Labs (CSE: CL) was the latest cannabis operator to report earnings this morning for the second quarter. Growth has slowed for the company, whom only saw 1.8% growth on a sequential basis, and 4% growth on a year over year basis.

Recognizing the growth story is aging quickly, CEO Charles Bachtell commented within the release, “Over the next three years, growth will come from the transition to adult use in seven large markets: New Jersey, New York, Pennsylvania, Ohio, Virginia, Florida and Maryland. Our combined footprint with Columbia Care, gives us exposure to all of these markets and leading positions in several. This is arguably the highest value footprint in cannabis – 180 million Americans and all 10 of the 10 highest projected 2025 revenue states.”

Revenue for the quarter amounted to $218.2 million, versus $214.4 million in the first quarter. Margins however improved slightly, climbing from 50.1% to that of 51.7% on a sequential basis.

Operating expenses meanwhile climbed to $90.1 million, lead by SG&A of $77.9 million. Income from operations as a result totaled $22.7 million.

After other expenses of $7.3 million and income tax expenses of $23.6 million, the firm reported a net loss of $8.3 million for the quarter, versus a loss of $23.7 million in the first quarter. Adjusted EBITDA declined slightly on a sequential basis, falling from $50.7 million to $50.6 million in the second quarter.

The major item for the second quarter appears to be the firms cash position, which fell substantially from $179.3 million to $89.5 million. Total current assets meanwhile dropped from $399.8 million to that of $314.3 million over the three month period, while total liabilities fell from $331.2 million to that of $228.2 million.

In terms of the acquisition of Columbia Care (CSE: CCHW), the company expects the transaction to clear “around year-end.” Divestiture and regulatory processes are reportedly on track at this point in time for the transaction to proceed, with Columbia Care shareholders approving the transaction in July. Court approval was granted several days later.

Cresco Labs last traded at $4.81 on the CSE.


Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

A Medical Breakthrough the Market Overlooked | David Elsley – Cardiol Therapeutics

Why Grade Beats Size in Silver Mining | Frank Basa – Nord Precious Metals

Are Investors Missing the Start of the Next Commodity Supercycle? | Morgan Lekstrom – NexMetals

Recommended

Emerita Resources Expands El Cura Drill Program By 10,000 Metres As Deposit Remains Open For Expansion

ESGold Signs MOU For Tailings Project In Colombia With Grades Up To 42 g/t Gold, 280 g/t Silver

Related News

Cresco Labs Finally Closes Acquisition of Origin House

The acquisition of Origin House (CSE: OH) by Cresco Labs (CSE CL) has finally closed...

Wednesday, January 8, 2020, 09:53:28 AM

Cresco Labs: Consensus First Quarter 2021 Estimates

Cresco Labs (CSE: CL) announced that they will be reporting their first quarter financials before...

Tuesday, May 25, 2021, 11:51:00 AM

Cresco Labs: Analyst Expectations For Q2 2021

Cresco Labs (CSE: CL) announced that they will be reporting their second quarter financials before...

Wednesday, August 11, 2021, 04:28:00 PM

Cresco Labs: Analysts Raise Targets Following Massachusetts Acquisition

On March 18th, Cresco Labs (CSE: CL) announced the acquisition of Cultivate, a Massachusetts-based vertically...

Tuesday, March 23, 2021, 11:53:00 AM

Cresco Labs Insiders Unload $32.8 Million Worth Of Shares In Early Morning Trade

Yesterday morning, popular cannabis investor Todd Harrison commented on Twitter that unusual trading activity had...

Tuesday, December 8, 2020, 07:17:38 AM